Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery

Author(s): Agnieszka Zagorska*, Anna Partyka, Adam Bucki, Alicja Gawalskax, Anna Czopek, Maciej Pawlowski .

Journal Name: Current Medicinal Chemistry

Volume 25 , Issue 29 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Background: The phosphodiesterase 10 (PDE10) family, identified in 1999, is mainly expressed in the brain, particularly in the striatum, within the medium spiny neurons, nucleus accumbens, and olfactory tubercle. Inhibitors of PDE10 (PDE10-Is) are a conceptually rational subject for medicinal chemistry with potential use in the treatment of psychiatric and neurodegenerative diseases.

Objective: This review is based on peer-reviewed published articles, and summarizes the cellular and molecular biology of PDE10 as a rational target for psychiatric and neurodegenerative drug discovery. Here, we present the classification of PDE10-Is from a medicinal chemistry point of view across a wide range of different, drug-like chemotypes starting from theophylline and caffeine analogs, papaverine and dimethoxy catechol type PDE10-Is, TP-10, MP-10, MP-10/papaverine/quinazoline series inhibitors, and ending with the newest inhibitors obtained from fragment-based lead discovery (FBLD). The authors have collated recent research on inhibition of PDE10A as a promising therapeutic strategy for psychiatric and neurodegenerative diseases, based on its efficacy in animal models of schizophrenia, Parkinson’s, Huntington’s, and Alzheimer’s diseases. This review also presents pharmacological data on PDE10-Is as possible therapeutics for the treatment of cognitive deficits, obesity and depression. Moreover, it summarizes the current strategies for PDE10-Is drug discovery based on the results of clinical trials. The authors also present the latest studies on crystal structures of PDE10 complexes with novel inhibitors.

Keywords: Phosphodiesterase 10, PDE10 inhibition, CNS drug development, antipsychotics, schizophrenia, Parkinson’s disease, cognition.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 25
ISSUE: 29
Year: 2018
Page: [3455 - 3481]
Pages: 27
DOI: 10.2174/0929867325666180309110629
Price: $58

Article Metrics

PDF: 68
HTML: 8
PRC: 3